[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019041778A1 - Utilisations de la muscone dans la préparation de médicaments pour le traitement de maladies autoimmunes - Google Patents

Utilisations de la muscone dans la préparation de médicaments pour le traitement de maladies autoimmunes Download PDF

Info

Publication number
WO2019041778A1
WO2019041778A1 PCT/CN2018/077989 CN2018077989W WO2019041778A1 WO 2019041778 A1 WO2019041778 A1 WO 2019041778A1 CN 2018077989 W CN2018077989 W CN 2018077989W WO 2019041778 A1 WO2019041778 A1 WO 2019041778A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
treating
neuroimmune
use according
medicament
Prior art date
Application number
PCT/CN2018/077989
Other languages
English (en)
Chinese (zh)
Inventor
王少侠
胡利民
闵江
张玥
郭虹
甘国峰
Original Assignee
无锡济民可信山禾药业股份有限公司
天津中医药大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 无锡济民可信山禾药业股份有限公司, 天津中医药大学 filed Critical 无锡济民可信山禾药业股份有限公司
Publication of WO2019041778A1 publication Critical patent/WO2019041778A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin

Definitions

  • the invention relates to the use of musk ketone, in particular to the use of musk ketone in the preparation of a medicament for treating neuroimmune diseases.
  • Musk ketone is from the genus Moschus berezovskii Flerov or the original Moschus moschiferus L.
  • Parkinson's disease is a common dyskinesia disease in middle-aged and elderly people, also known as tremor palsy.
  • the main pathological changes are degeneration and necrosis of dopaminergic neurons in the midbrain and Lewy bodies in the brain. form.
  • the main clinical manifestations are static tremor, muscle rigidity, and retardation.
  • the etiology of Parkinson's disease and the precise mechanism of degeneration of dopaminergic neurons have not yet been fully elucidated. Parkinson's disease is still an incurable progressive disease, and the current treatment is essentially to improve the quality of life and work ability of patients.
  • the incidence of this disease has a clear upward trend. The most conservative estimate is that the incidence of Parkinson's disease in China has increased by at least 20 times in the past 20 years, which is as high as 2%.
  • Multiple sclerosis is a central nervous system inflammatory demyelinating disease caused by autoimmune abnormalities. Remission-recurrence is an important feature in the course of the disease and is the most common cause of neurological disability in young adults. The exact etiology and pathogenesis are unknown, but multiple sclerosis is considered to be an autoimmune disease mediated primarily by CD4+ T cells.
  • Currently used drugs for the treatment of multiple sclerosis include immunomodulators and immunosuppressive agents, such as beta interferon (IFN- ⁇ ), glatiramer, novantrone, etc., but the above The drugs are administered parenterally, the patients are inconvenient to use, and the adverse reactions are large.
  • IFN- ⁇ beta interferon
  • glatiramer glatiramer
  • novantrone novantrone
  • Huntington's disease is a hereditary degenerative brain disease, and the cause of Huntington's disease is a mutation in the Huntingtin gene. Although the formation of the corresponding mutant Huntington's protein (Htt) polymer is related to the pathogenesis of Huntington's disease, it is still unclear whether it really causes damage to the nervous system. There is currently no effective method for treating Huntington's disease.
  • microglia are central nervous system immune cells. In the pathological state of Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis, Bengal disease, etc., small changes in the microenvironment can activate microglia. To quickly move from a resting state to an activated state.
  • the whole activation process presents a waterfall effect: differentiation, proliferation, up-regulation of expression or expression of immune molecules, migration to the site of injury, morphogenesis, immunodominance and functional changes. Its morphologically increased volume, rounded body and deformation, phagocytosis; functionally began to express a large number of membrane surface molecules related to antigen recognition and presentation, such as the expression of major histocompatibility complex II (MHC); Overexpression of matrix protease 9 (MMP9) degrades the blood-brain barrier.
  • MHC major histocompatibility complex II
  • MMP9 matrix protease 9
  • cytokines are significantly up-regulated, and a small part of them such as GDNF promotes neuronal survival, and most of them are tumor necrosis factor alpha (TNF ⁇ ), interleukin-1 ⁇ (IL-1 ⁇ ), and interleukin-6 (IL-6).
  • TNF ⁇ tumor necrosis factor alpha
  • IL-1 ⁇ interleukin-1 ⁇
  • IL-6 interleukin-6
  • chemokines such as monocyte chemoattractant protein 1 (MCP-1), irregular chemokine (Fractalkine), macrophage inflammatory protein 1 (MIP-1) Leukocyte chemotaxis; also produces nitric oxide (NO), reactive oxygen species (ROS) and eicosanoids (such as prostaglandin E2), leading to secondary brain damage.
  • MCP-1 monocyte chemoattractant protein 1
  • Rhtalkine irregular chemokine
  • MIP-1 macrophage inflammatory protein 1
  • MIP-1 macrophage inflammatory protein 1
  • Microglia are not only
  • musk ketone has prevention and treatment of myocardial infarction (China Pharmaceuticals, 2010, 19: 12-13), thrombosis (Journal of Kunming Medical College, 2006, 4: 1-5), and anti-cancer (Phytomedicine, 2010, 17 :63-68) and protect the liver (J Asian Nat Prod Res, 2010, 12: 175-184) and other functions.
  • musk ketone has not been reported to inhibit microglia-mediated neurotoxicity and to prevent Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis, and Gujarat disease.
  • microglia is one of the main causes of neurological damage during the pathological development of Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis, and Bengal disease.
  • Excessive activation of cytoplasmic cells can effectively prevent and treat the above-mentioned brain inflammatory related diseases.
  • Neuroimmune inflammatory diseases such as Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis, and Gujarat disease caused by mediated neurotoxic effects are still expected by those skilled in the art.
  • the object of the present invention is to provide a musk ketone in the preparation of a medicament for treating a neuroimmune disease, in particular, a drug for neuroimmune diseases caused by microglia-mediated neurotoxicity, and preparation of musk ketone
  • a neuroimmune disease in particular, a drug for neuroimmune diseases caused by microglia-mediated neurotoxicity, and preparation of musk ketone
  • the resulting drug has an unexpected therapeutic effect on neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Gujarat.
  • the present invention provides a use of muscone in the preparation of a medicament for treating a neuroimmune disease.
  • the medicament for treating a neuroimmune disease is a medicament for treating a neuroimmune disease caused by a neurotoxic effect.
  • the medicament for treating a neuroimmune disease is a medicament for treating a neuroimmune disease caused by a microglial-mediated neurotoxicity.
  • the medicament for treating a neuroimmune disease is a medicament for treating a neuroimmune disease caused by secretion of an inflammatory medium by microglia.
  • the medicament for treating a neuroimmune disease is a neuroimmune disease drug caused by the treatment of release of microglia NO, TNF- ⁇ , and IL-6.
  • the medicament for treating a neuroimmune disease is a neuroimmune disease drug caused by the treatment of lipopolysaccharide-induced release of microglia NO, TNF- ⁇ , IL-6.
  • the medicament for treating a neuroimmune disease is a medicament for treating Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Tamil disease.
  • the medicine for treating neuroimmune diseases is prepared by using musk ketone as a raw material, according to a conventional preparation process, and then adding corresponding auxiliary materials to prepare any oral or injectable dosage form suitable for clinical use.
  • the oral or injectable dosage form comprises a tablet, a granule, a capsule, a pill, a soft capsule, an oral solution, a syrup, a dispersible tablet, an intravenous injection or an intramuscular injection.
  • the excipients include conventional solvents, disintegrants, flavoring agents, preservatives, colorants, binders, lubricants, wetting agents, thickeners, and solubilizers.
  • the muscone of the present invention is an existing product which is commercially available or can be prepared by the following method:
  • the present invention provides the use of muscone in the preparation of a medicament for treating a neuroimmune disease, in particular, a neuroglial disease drug caused by microglia-mediated neurotoxicity,
  • a neuroimmune disease in particular, a neuroglial disease drug caused by microglia-mediated neurotoxicity
  • the preparation of musk ketone has an unexpected therapeutic effect on neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Tamil disease.
  • Figure 1 shows the effect of musk ketone on the viability of microglia cells.
  • Figure 2 shows that musk ketone inhibits the release of NO from microglia by LPS (lipopolysaccharide).
  • Figure 3 shows that musk ketone inhibits LPS-induced release of TNF-[alpha] from microglia.
  • Figure 4 shows that musk ketone inhibits LPS-induced IL-6 release from microglia.
  • musk ketone Taking 1-100g of musk ketone, adding the conventional excipients for preparing tablets, and making 1000 tablets according to the conventional preparation process of tablets, for preventing and treating neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, Encephalitis or Tamil's disease, 0.1-1 g per tablet, 1-3 tablets each time, 1-3 times a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, Encephalitis or Tamil's disease
  • 0.1-1 g per tablet 1-3 tablets each time, 1-3 times a day.
  • musk ketone Take 1-100 g of musk ketone, add the conventional excipients for preparing capsules, mix them, and put them into capsules to make 1000 capsules.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Gujarat disease, each containing muskone 1-100mg, 1-3 capsules per day, 1-day 3 times.
  • musk ketone Taking 1-100g of musk ketone, adding conventional excipients for preparing granules, and making 1000 bags according to the conventional preparation process of granules, for preventing and treating neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis Or Gujarat disease, 1-10 grams per bag, 0.5-2 bags each time, 1-3 times a day.
  • musk ketone Take 1-100g of musk ketone, add the conventional excipients for preparing oral liquid, and make 1000 pieces according to the conventional preparation process of oral liquid for prevention and treatment of neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis Or Gujarat disease, each 1ml-10ml, 1-3 each time, 1-3 times a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis Or Gujarat disease, each 1ml-10ml, 1-3 each time, 1-3 times a day.
  • musk ketone Take 1-100g of musk ketone, add conventional raw materials for injection preparation, and make 1000 injections for prevention and treatment of neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Tamil disease , each 5ml-10ml.
  • Adult intravenous or intramuscular injection 1-3 times a day, once a day.
  • musk ketone Take 1-100g of musk ketone, add the conventional excipients for preparing syrup, and make 1000 pieces according to the conventional preparation process of syrup, for preventing and treating neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis Or Gujarat disease, each 50-250ml, 2-10ml each time, 1-3 times a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis Or Gujarat disease, each 50-250ml, 2-10ml each time, 1-3 times a day.
  • musk ketone Take 5g of musk ketone, add the auxiliary materials for preparing tablets, and make 1000 tablets according to the conventional preparation process of tablets, for preventing and treating neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Tamil disease, 2 tablets each time, 2 times a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Tamil disease
  • the content of each component of the tablet includes:
  • musk ketone 100 g of starch, 10 g of carboxymethyl cellulose, 10 g of calcium carbonate, and 5 g of talc.
  • musk ketone 5 g was added, and the preparation of the capsule was added, mixed, and filled into capsules to prepare 1000 tablets.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Gujarat disease, 2 capsules each time, 2 times a day.
  • each component of the capsule includes:
  • musk ketone Take 5g of musk ketone, add the auxiliary material for preparing granules, and make 1000 bags according to the conventional preparation process of granules, for preventing and treating neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Guca Lei disease, 1 bag each time, 2 times a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Guca Lei disease
  • the content of each component of the granules includes:
  • musk ketone Take 5g of musk ketone, add the auxiliary material for preparing oral liquid, and make 1000 pieces according to the conventional preparation process of oral liquid for prevention and treatment of neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Guca Lei disease, 1 each time, 2 times a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Guca Lei disease
  • the content of each component of the oral liquid includes:
  • musk ketone 5 g of musk ketone, 150 ml of ethanol, 100 g of glucose, 20 g of sodium carboxymethylcellulose, 25 g of polyethylene glycol, and water.
  • musk ketone Take 5g of musk ketone, add the raw materials for the preparation of injection, and make 1000 injections for the prevention and treatment of neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Tamil disease, adult vein Or intramuscular injection, 2 each time, once a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Tamil disease, adult vein Or intramuscular injection, 2 each time, once a day.
  • the content of each component of the injection includes:
  • musk ketone Take 5g of musk ketone, add the auxiliary material for preparing syrup, and make 1000 pieces according to the conventional preparation process of syrup, for prevention and treatment of neuroimmune diseases, especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Guca Ray disease, 10ml each time, 2 times a day.
  • neuroimmune diseases especially Parkinson's disease, multiple sclerosis, Huntington's disease, encephalitis or Guca Ray disease, 10ml each time, 2 times a day.
  • each component of the syrup comprises:
  • musk ketone 5 g of musk ketone, 200 ml of ethanol, 300 g of sucrose, 20 g of sodium carboxymethylcellulose, 50 ml of peppermint oil, and 10 g of sorbic acid.
  • the BV-2 mouse microglia cell line was purchased from the Institute of Basic Research of the Chinese Academy of Medical Sciences.
  • BV-2 cells were cultured in DMEM + 10% FBS + 1% double-antibody culture medium and trypsinized every 3 days. 5% CO2, 95% air, cultured at 37 ° C saturated humidity. The cells in the log phase were harvested and inoculated in a 96-well plate (4 ⁇ 105 cells/mL, 100 ⁇ L/well) overnight in a 37°C incubator. The prepared musk ketone (10-5 mol/L) was added and discarded after 24 hours. The supernatant was added to prepare a medium containing 10% CCK-8, incubated at 37 ° C for 30 min, and the absorbance value was read at 450 nm.
  • the cells in the log phase were harvested and inoculated in a 48-well plate (4 ⁇ 105 cells/mL, 400 ⁇ L/well) overnight in a 37°C incubator.
  • the blank control group and the LPS group were incubated with the basic culture medium for 30 min, and the musk ketone was treated.
  • the group was treated with musk ketone (final concentration 10-5mol/L) for 30min, LPS group was added with LPS at a final concentration of 0.1 ⁇ g/mL, muscone intervention group was added with LPS and musk ketone, and NO and TNF- ⁇ were detected after 24h.
  • IL-6 content The blank control group and the LPS group were incubated with the basic culture medium for 30 min, and the musk ketone was treated.
  • the group was treated with musk ketone (final concentration 10-5mol/L) for 30min, LPS group was added with LPS at a final concentration of 0.1 ⁇ g/mL, muscone intervention group was added
  • the Griess method detects the reaction of NO:NO 2+ with Griess reagent to form a red compound, and the color depth is proportional to the content of NO 3+ /NO 2+ in the system.
  • the content of TNF- ⁇ and IL-6 was determined by ElISA method: 1 The supernatant of the obtained cell was centrifuged at 10000 g for 15 minutes, diluted 6 times, and used. Add the sample to the sample well, cover the membrane, and incubate for 2 h at room temperature; 2 discard the supernatant, add 300 ⁇ l/well to the 1 ⁇ washing buffer for 5 times, 5 min/time, and finally blot dry with filter paper to add specificity.
  • Test Example 3 Clinical experiment of musk ketone
  • METHODS A total of 350 patients with PD admitted to the Chinese Medicine Hospital from April 2012 to December 2016 were enrolled.
  • the patients were randomly divided into 7 groups: 6 groups in the observation group, specifically in groups 7-12.
  • the muscone-containing preparations prepared in Examples 7-12 were combined with levodopa for treatment of Parkinson's disease in 50 patients in each group; 50 patients in the control group received levodopa for treatment of Parkinson's disease.
  • the clinical efficacy of the 7 groups of patients and the UPDRS score before and after treatment were compared. The results are shown in Table 1.
  • RESULTS Studies have shown that musk ketone has an improved effect on motor and affective disorders in patients with (PD).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une utilisation de la muscone dans la préparation de médicaments pour le traitement de maladies neuroimmunitaires, les maladies neuroimmunitaires se rapportant aux maladies neuroimmunitaires provoquées par des effets neurotoxiques à médiation par la microglie, y compris la maladie de Parkinson, la sclérose en plaques, la maladie de Huntington, l'encéphalite ou la maladie de Gujarat.
PCT/CN2018/077989 2017-09-04 2018-03-05 Utilisations de la muscone dans la préparation de médicaments pour le traitement de maladies autoimmunes WO2019041778A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710786903.0 2017-09-04
CN201710786903.0A CN107714679A (zh) 2017-09-04 2017-09-04 麝香酮的新用途

Publications (1)

Publication Number Publication Date
WO2019041778A1 true WO2019041778A1 (fr) 2019-03-07

Family

ID=61205628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/077989 WO2019041778A1 (fr) 2017-09-04 2018-03-05 Utilisations de la muscone dans la préparation de médicaments pour le traitement de maladies autoimmunes

Country Status (2)

Country Link
CN (1) CN107714679A (fr)
WO (1) WO2019041778A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107714679A (zh) * 2017-09-04 2018-02-23 无锡济民可信山禾药业股份有限公司 麝香酮的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106798736A (zh) * 2017-02-14 2017-06-06 南京鼓楼医院 麝香酮制备治疗阿尔茨海默病药物的应用
CN107714679A (zh) * 2017-09-04 2018-02-23 无锡济民可信山禾药业股份有限公司 麝香酮的新用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106798736A (zh) * 2017-02-14 2017-06-06 南京鼓楼医院 麝香酮制备治疗阿尔茨海默病药物的应用
CN107714679A (zh) * 2017-09-04 2018-02-23 无锡济民可信山禾药业股份有限公司 麝香酮的新用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SHI, JINFENG: "Protective Effect of Musk Extract on Rat's Cerebral Cortical Neurons with Inflammatory Injury", MASTER'S THESIS OF ZHENGZHOU UNIVERSITY , MEDICAL AND HEALTH TECHNOLOGY SERIES, 30 June 2011 (2011-06-30), pages 10 - 13 *
ZHANG ZHUANG ET AL.: "Protective Effects of Muscone on the Hypoxia/Hypoglycemia and Reoxygenation Induced Damage of SH-SY5Y Nerve Cell Cultured in Vitro", CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE IN INTENSIVE AND CRITICAL CARE, vol. 14, no. 6, 28 November 2007 (2007-11-28), pages 340 - 343, XP055579058 *
ZUO, LIJUN ET AL.: "Neuroimmune Inflammation and Alzheimer's Disease", CHINESE JOURNAL OF CLINICIANS, vol. 7, no. 14, 31 July 2013 (2013-07-31), pages 6547 - 6550 *

Also Published As

Publication number Publication date
CN107714679A (zh) 2018-02-23

Similar Documents

Publication Publication Date Title
US11517604B2 (en) Method for preparing Plectranthus amboinicus fraction having anti-arthritis activity
Tang et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia
AU2010242967A1 (en) Neuroprotective ganoderma compositions and methods of use
WO2018113027A1 (fr) Application du bilobalide comme activateur dans la préparation de médicaments pour la prévention de maladies de type lésions de nerfs crâniens
WO2011153678A1 (fr) Composition contenant des iridoïdes et ses utilisations
WO2011088715A1 (fr) Utilisation d'albiflorine pour le traitement de la maladie de parkinson
CN110755386B (zh) 百蕊颗粒在制备治疗病菌感染导致高热症的药物中的应用
WO2019041778A1 (fr) Utilisations de la muscone dans la préparation de médicaments pour le traitement de maladies autoimmunes
EP1682162B1 (fr) Utilisation de figue de barbarie (opuntia) pour la préparation d'un médicament pour le traitment des depressions
JP2872809B2 (ja) モノシアロガングリオシドｇｍ▲下１▼またはその誘導体を含有する，パーキンソン病の治療に適する医薬組成物
CN109939119B (zh) 栀子苷在制备治疗多发性硬化症药物中的应用
CN104288168A (zh) 延龄草苷在制备用于治疗和/或预防小胶质细胞介导的疾病的药物中的用途
CN109419787B (zh) 一种松香烷型二萜类化合物的用途
WO2015165382A1 (fr) Acide ganodérique a utilisé comme antidépresseur
KR102374820B1 (ko) 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물
US11638736B2 (en) Compositions for preventing or treating diseases or disorders associated with neuro-inflammation, neuro-apoptosis, or neuro- oxidative damage and uses thereof
WO2014133286A1 (fr) Composition contenant des extraits d'artemisia iwayomogi et de curcuma longa en tant que principes actifs pour la prévention, l'inhibition ou le traitement de maladies se rapportant à l'obésité
EP2830641B1 (fr) Nouveaux extraits de valeriane et leurs utilisations
CN1994277A (zh) 一种丹参丹酚酸a固体制剂及其制备方法
WO2020207398A1 (fr) Utilisation de lactone terpénique de ginkgo dans la préparation d'un médicament pour la prévention et/ou le traitement du syndrome de guillain-barré-strohl
CN112472725A (zh) 褐藻提取物及其应用
CN106822152B (zh) 一种药物组合物及其应用
JP2729340B2 (ja) 痴呆症治療剤
CN115154448B (zh) 一种治疗不宁腿综合征的药物及其制备方法和应用
US20240269104A1 (en) Method for treating parkinson's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18850431

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18850431

Country of ref document: EP

Kind code of ref document: A1